private:sanarusmedical
|
43029
|
May 31st, 2019 12:00AM
|
Sanarus Technologies
|
958
|
28.00
|
Open
|
Medical Devices
|
May 31st, 2019 03:33PM
|
May 31st, 2019 03:33PM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
Open
|
Surgical Alternatives, Cryoablation, Breast Care, Breast Tumors, interventional radiology, radiology, diagnostic imaging, minimally invasive treatment
|
Open
|
1249 Quarry Lane, Suite 150
|
Pleasanton
|
California
|
US
|
94566
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Mar 18th, 2018 12:00AM
|
Sanarus Technologies
|
858
|
30.00
|
Open
|
Medical Devices
|
Mar 18th, 2018 04:05PM
|
Mar 18th, 2018 04:05PM
|
|
Open
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 17th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 16th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 15th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 14th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 13th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 12th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 11th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|
private:sanarusmedical
|
43029
|
Feb 10th, 2018 12:00AM
|
Sanarus Technologies
|
834
|
32.00
|
Open
|
Medical Devices
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S.
The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection.
Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery.
www.sanarus.com
www.twitter.com/SanarusTech
|
|
|
|
|
|
|
|
|
|
Sanarus Medical
|
|
Health Care Equipment & Services
|